What is the milligram‑to‑milligram conversion when switching from divalproex (valproate semisodium) to sodium valproate, and are any dose adjustments or monitoring needed?

Conversion Between Divalproex and Sodium Valproate

Direct Answer

When converting from divalproex (valproate semisodium) to sodium valproate, use a 1:1 milligram-to-milligram conversion with no dose adjustment required, as both formulations deliver equivalent amounts of valproic acid at steady state. 1, 2

Pharmacokinetic Equivalence

• Divalproex sodium (also called divalproex or valproate semisodium) and sodium valproate are chemically related salts that deliver the same active moiety—valproic acid—and can be interconverted on a 1:1 mg basis without dose modification. 2

• Both formulations achieve comparable steady-state plasma valproic acid concentrations when administered at identical total daily doses, making direct milligram-for-milligram substitution appropriate. 1, 2

Conversion Strategy

Perform an immediate overnight conversion by administering the first dose of sodium valproate 12 hours after the last dose of divalproex, using the same total daily dose. 3, 2

• This immediate conversion strategy (switching "all-at-once" 12 hours after the last divalproex dose) causes the least perturbation in plasma valproic acid concentrations and maintains therapeutic levels throughout the transition. 3

• Alternative strategies such as delayed conversion or stepwise titration offer no advantage and may result in subtherapeutic valproic acid concentrations, particularly in patients on enzyme-inducing co-medications. 3

Monitoring Requirements

Measure trough valproic acid levels 2 weeks after conversion to confirm therapeutic concentrations (target range 50–100 mg/L). 2

• Routine monitoring is particularly important in patients with:

  • Enzyme-inducing co-medications (e.g., carbamazepine, phenytoin) 3, 4
  • Known or suspected malabsorption 5
  • Renal impairment 5
  • Poor treatment response 5

• No significant difference in serum trough valproic acid levels occurs when converting at the same total daily dose, regardless of whether the original divalproex was given once-daily, twice-daily, or multiple times daily. 2

Clinical Outcomes

• Seizure control remains stable following 1:1 conversion, with mean seizure frequency unchanged (3.35 seizures/month pre-conversion versus 3.29 post-conversion). 2

• Adverse effects typically remain stable or improve after conversion, with some patients reporting improvements in tremor, weight gain, and gastrointestinal symptoms. 2

• Long-term retention rates are favorable, with 77.5% of patients remaining on therapy after conversion. 2

Important Caveat: Extended-Release Formulations

Do NOT use a 1:1 conversion if switching from immediate-release or delayed-release divalproex to extended-release divalproex (Depakote ER), as this requires an 8–20% dose increase. 1

• Extended-release divalproex has approximately 89% bioavailability compared to conventional divalproex, necessitating higher total daily doses to achieve equivalent exposure. 1

• This caveat does NOT apply to standard immediate-release or delayed-release formulations of divalproex versus sodium valproate, which are bioequivalent. 1, 2